ADIL Average Annual Return Since 2018
Growth of $10,000.00
Without Dividends Reinvested Into ADIL


Also see:
ADIL stock yearly return 2019
ADIL stock yearly return 2020
ADIL stock yearly return 2021
ADIL stock yearly return 2022
ADIL stock yearly return 2023
ADIL YTD return
Compare ADIL average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 07/30/2018
End date: 06/24/2024
Start price/share: $100.25
End price/share: $1.15
Dividends collected/share: $0.00
Total return: -98.85%
ADIL Average Annual Return: -53.06%
Starting investment: $10,000.00
Ending investment: $114.78
Years: 5.91


ADIL average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
ADial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Co.'s investigational new drug product, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. Co. has a license from the University of Virginia Patent Foundation to commercialize its AD04. The active pharmaceutical agent in AD04, Co.'s investigational new drug product, is ondansetron, which is also the active ingredient in Zofran®, an approval for nausea and vomiting post-operatively and after chemotherapy or radiation treatment and is commercially available in generic form. The ADIL average annual return since 2018 is shown above.

The Average Annual Return on the ADIL average annual return since 2018 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether ADIL average annual return since 2018 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the ADIL average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree ADIL Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
ADial Pharmaceuticals (ADIL) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

ADMA Average Annual Return
ADPT Average Annual Return
ADTX Average Annual Return
ADUS Average Annual Return
ADVM Average Annual Return
AEMD Average Annual Return
AEZS Average Annual Return
AFIB Average Annual Return
AGEN Average Annual Return
AGIO Average Annual Return
More Healthcare companies »

 

ADIL Average Annual Return Since 2018 | www.AverageAnnualReturn.com | Copyright © 2021 - 2024, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.